Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma
Replimune Group, Inc. announced a favorable outcome from the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee regarding the Biologics License Application resubmission for RP1, an oncolytic immunotherapy, used in combination with nivolumab to treat advanced melanoma patients who progressed after prior anti-PD-1 therapy. The committee vo…